Valuation: Annexon, Inc.

Market Cap 760M 678M 628M 571M 1.07B 72.16B 1.09B 7.54B 2.96B 37.68B 2.85B 2.79B 121B P/E 2026 *
-3.84x
P/E 2027 * -4.11x
Enterprise Value 682M 608M 564M 512M 961M 64.7B 977M 6.76B 2.65B 33.79B 2.56B 2.5B 108B EV / Sales 2026 *
-
EV / Sales 2027 * 19.7x
Free-Float
94.43%
Yield 2026 *
-
Yield 2027 * -
1 day+17.60%
1 week-0.25%
Current month-5.20%
1 month-5.20%
3 months-30.86%
6 months-38.69%
Current year-20.12%
1 week 3.36
Extreme 3.355
4.03
1 month 3.36
Extreme 3.355
4.38
Current year 3.36
Extreme 3.355
7.18
1 year 2.54
Extreme 2.54
7.18
3 years 1.28
Extreme 1.285
8.4
5 years 1.28
Extreme 1.285
21.28
10 years 1.28
Extreme 1.285
38.01
Manager TitleAgeSince
Chief Executive Officer 58 01/12/2014
Director of Finance/CFO 53 01/06/2019
Chief Tech/Sci/R&D Officer 68 27/07/2023
Director TitleAgeSince
Director/Board Member 58 01/12/2014
Director/Board Member 67 05/02/2021
Director/Board Member 56 01/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
24/09/26 Buy

Chief Executive Officer

26,065 0.0137%
10/08/26 Free

Director

175,000 0.0923%
28/05/26
Alerce Investment Management LP
BuyCompany 613,497 0.3775%
Change 5-day change 1-year change 3-year change Capi.($)
+17.60%-0.25%+27.30%+133.14% 646M
+1.52%-7.16%+51.66%+67.41% 65B
+1.52%+7.17%+10.77%+77.89% 51.2B
+0.30%+0.19%+2.53%+56.14% 51.19B
-0.38%+2.31%+29.98%+40.71% 43.93B
+0.30%+4.43%+16.99%+120.94% 41.96B
+2.35%-4.01%+236.69%+497.21% 38.14B
+2.16%+10.36%+18.92%+59.70% 33.24B
-0.90%-10.49%+37.09%+1.80% 25.2B
+1.60%+3.97%+21.34%+22.33% 22.5B
Average +2.61%-1.39%+45.33%+107.73% 37.3B
Weighted average by Cap. +1.00%+0.01%+46.00%+106.41%

Financials

2026 *2027 *
Net sales - 35.32M 31.5M 29.2M 26.54M 49.81M 3.35B 50.6M 350M 137M 1.75B 133M 130M 5.6B
Net income -213M -190M -176M -160M -301M -20.23B -305M -2.11B -830M -10.56B -800M -783M -33.78B -216M -193M -179M -162M -305M -20.5B -309M -2.14B -841M -10.71B -810M -793M -34.24B
Net Debt -78.52M -70.02M -64.91M -59.01M -111M -7.45B -112M -778M -306M -3.89B -295M -288M -12.45B -63.35M -56.49M -52.36M -47.61M -89.34M -6.01B -90.75M -628M -247M -3.14B -238M -233M -10.04B
Projected Income Statement - Annual - Annexon, Inc.
Logo Annexon, Inc.
Annexon, Inc. is a biopharmaceutical company advancing targeted immunotherapies aimed at complement-mediated neuroinflammatory diseases. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Tanruprubart is an investigational-targeted immunotherapy delivered in a single infusion to rapidly halt aggressive neuroinflammation and damage in GBS, an acute, rare, neuromuscular emergency. The Vonaprument is an investigational neuroprotective inhibitor of C1q and the classical complement cascade delivered intravitreally for dry AMD with GA, a leading cause of blindness. ANX1502, a novel oral small molecule for autoimmune conditions. The Company's next wave programs include ANX005 and ANX009. ANX009, a C1q-blocking Fab formulated for subcutaneous delivery, for patients with lupus nephritis.
Employees
92
Date Price Change Volume
19/10/26 $4.010 +17.60% 6,233,338
16/10/26 $3.410 -5.28% 5,240,023
15/10/26 $3.600 -1.91% 2,653,845
14/10/26 $3.670 -4.18% 4,042,922
13/10/26 $3.830 -3.28% 3,421,698
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Annexon, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.410USD
Average target price
17.00USD
Spread / Average Target
+398.53%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Annexon, Inc.
  1. Stock Market
  2. Stocks
  3. ANNX Stock